About ESWI2025

Preliminary programme

Preliminary programme

Sun 19 Oct 2025
17:00 - 20:00
Poster mounting REG02
Poster Halls
Ended Now live Upcoming
Registration desk open REG01
Registration desk
Ended Now live Upcoming
 
Mon 20 Oct 2025
09:00 - 18:00
Registration desk open REG03
Registration desk
Ended Now live Upcoming
10:00 - 11:00
PLE
Plenary opening and keynotes PLE01
Auditorium 1 - Plenary Hall
Chairs
Colin RUSSELL
ESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands
Read more
Ab OSTERHAUS
ESWI Board Member, TiHO, Germany
Read more
Stefania MAGGI
ESWI Board Member, National Research Council of Italy, Italy
Read more
Marco GOEIJENBIER
ESWI Board Member, Spaarne Gasthuis, Netherlands
Read more
Ended Now live Upcoming
11:00 - 11:30
Coffee Break COF01
Exhibition hall
Ended Now live Upcoming
Poster mounting REG04
Poster Halls
Ended Now live Upcoming
11:30 - 13:00
SCS
Innate and adaptive immunity SCS01
Auditorium 1 - Plenary Hall
Chairs
Guus RIMMELZWAAN
University of Veterinary Medicine, Hannover, Germany
Read more
Kevin SELVA
Doherty Institute, University of Melbourne, Australia
Read more
Ended Now live Upcoming
  1. Increasing SARS-CoV-2 IgG4 following repeated mRNA boosters negatively impact antibody functions across Omicron variants and sarbecoviruses
    Kevin SELVADoherty Institute, University of Melbourne, Australia
  2. Impact of Aging on CD8+ T Cell Immunity to Circulating and Pandemic Viruses
    Carolien VAN DE SANDTESWI Associate Member, The University of Melbourne at the Doherty Institute, Australia
  3. Detection of pre-existing humoral immunity against influenza virus H5N1 clade 2.3.4.4b in unexposed individuals
    To be confirmed
  4. SYSTEMIC AND MUCOSAL ANTIBODY SIGNATURES OF PROTECTION AGAINST SARS-COV-2 TRANSMISSION
    To be confirmed
  5. Obesity modulates tracheal and cardiac responses to influenza A virus infection
    Betina Lyngfeldt HENRIKSENTechnical University of Denmark, Denmark
  6. Prior influenza vaccination shapes subsequent vaccine responses in a randomized placebo-controlled trial
    To be confirmed
SCS
Pandemic Preparedness SCS02
Auditorium 2 - Breakout
Chair
Ab OSTERHAUS
ESWI Board Member, TiHO, Germany
Read more
Ended Now live Upcoming
  1. Observed Immunogenicity After Two Doses of an MF59-Adjuvanted Cell Culture–Derived H5N8 Influenza Vaccine (aH5N8c) in Healthy Subjects Aged ≥18 Years
    To be confirmed
  2. Immunogenicity of Homologous or Heterologous Booster Vaccinations with MF59-Adjuvanted, Cell Culture–Derived H5N8 or H5N6 Influenza Vaccines in Healthy Subjects Aged ≥18 Years
    To be confirmed
  3. When can sequence data confirm transmission links in respiratory virus outbreaks?
    To be confirmed
  4. Broad-Spectrum Baseline Immunity Against Highly Pathogenic Avian Influenza A(H5N1) Clade 2.3.4.4b Viruses in Dutch Healthcare Workers: Insights into Both Humoral and Cellular Immune Responses
    To be confirmed
  5. Evaluating Cross-Protective Antibody Responses to Influenza A(H5N8) Vaccine in High-Risk Groups
    Oona LIEDESFinnish Institute for Health and Welfare, Finland
  6. OVX836, a Nucleoprotein based vaccine under clinical development, offers protection against Highly Pathogenic Avian Influenza viruses (H5N1 and H7N9) in mouse and ferret models
    To be confirmed
SPI
ESWI invites coalition partners: Lifecourse Immunisation SPI01
Auditorium 3 - Breakout
Chair
Stefania MAGGI
ESWI Board Member, National Research Council of Italy, Italy
Read more
Ended Now live Upcoming
13:00 - 14:30
Lunch LUN01
Exhibition hall
Ended Now live Upcoming
Poster mounting REG05
Poster Halls
Ended Now live Upcoming
13:15 - 14:15
SAT
Satellite Symposium organised by AstraZeneca: Unfolding the story of the immune response to intranasal live attenuated influenza vaccines SAT01
Auditorium 2 - Breakout
Ended Now live Upcoming
14:30 - 16:00
SCS
Future vaccination strategies - PART 1 SCS03
Auditorium 1 - Plenary Hall
Chairs
Florian KRAMMER
ESWI Board Member, Medical University of Vienna, Austria
Read more
Marios KOUTSAKOS
University of Melbourne, Australia
Read more
Ended Now live Upcoming
  1. A Dendritic Cell-targeting Approach to Deliver a Universal Influenza Vaccine Candidate to the Respiratory Mucosa
    Daryl LEENational University of Singapore, Singapore
  2. Development of a next-generation COVID-19 intranasal vaccine based on a multivalent NDV-HXP-S formulation.
    To be confirmed
  3. Superior protection and prevention of transmission upon influenza infection by adjuvanted mucosal vaccination in the guinea pig influenza model.
    To be confirmed
  4. Broad betacoronavirus immunity and SARS-CoV-2 protection induced by divergent spike-based nucleoside-modified vaccines
    To be confirmed
  5. The Additive Effect of Neuraminidase Inclusion in Influenza Vaccine Formulations using a Self-Amplifying RNA Platform
    Giuseppe PALLADINOCSL, United States
  6. Evaluation of a broadly protective influenza B virus vaccine based on mosaic hemagglutinin platforms in mice.
    To be confirmed
SCS
Virus and host factors in pathogenesis SCS04
Auditorium 2 - Breakout
Chairs
Debby VAN RIEL
ESWI Associate Member, Erasmus MC, Netherlands
Read more
Anders MADSEN
Haukeland University Hospital, Norway
Read more
Ended Now live Upcoming
  1. Avian influenza viruses re-shape the hormonal landscape by inducing pulmonary CYP19A1 expression in golden hamsters
    Sebastian BECKLeibniz Institute of Virology, Germany
  2. Obesity increases the risk for severe COVID 19 – An obese hamster model to study sex-specific differences in the underlying pathophysiology
    To be confirmed
  3. Inter-strain differences in influenza-host interactions in recent seasonal human influenza strains
    To be confirmed
  4. Functional Balance of HA and NA in Emerging Porcine Influenza A Viruses: Sialoreceptor Dynamics at the Mucosal Interface
    To be confirmed
  5. Cell Tropism, Replication Dynamics, and effect on neural network activity to Seasonal and Pandemic Influenza A Virus Infection in a hiPSC-Derived Neural Co-Culture Model
    To be confirmed
  6. Single-cell profiling of inflammatory lung injury in clade 2.3.4.4b H5N1 influenza infected mice
    Ying LIUThe University of Hong Kong, Hong Kong SAR China
SPI
Burden of disease in acute respiratory virus infections SPI02
Auditorium 3 - Breakout
Chairs
Paula TÄHTINEN
ESWI Board Member, Turku University Hospital and University of Turku, Finland
Read more
Stefania MAGGI
ESWI Board Member, National Research Council of Italy, Italy
Read more
Ended Now live Upcoming
  1. Risk factors associated with severe health outcomes among older adults hospitalized with respiratory syncytial virus (RSV): understanding the pre-vaccine era landscape
    To be confirmed
16:00 - 16:30
Coffee Break COF02
Exhibition hall
Ended Now live Upcoming
Poster mounting REG06
Poster Halls
Ended Now live Upcoming
16:30 - 17:30
SAT
Satellite Symposium SAT02
Auditorium 1 - Plenary Hall
Ended Now live Upcoming
SAT
Satellite Symposium organised by Pfizer: RSV Vaccination in Adults: Integrating Current Clinical Trial Data and Real-World Insights SAT03
Auditorium 2 - Breakout
Ended Now live Upcoming
SAT
Satellite Symposium organised by ISIRV: ISIRV 20th Anniversary Lecture: Use of antivirals in pandemics: what have we learnt? SAT04
Auditorium 3 - Breakout
Ended Now live Upcoming
17:30 - 19:00
Welcome Refreshments and networking DIN01
Exhibition hall
Ended Now live Upcoming
19:00 - 20:00
ECAS
Early Career Scientists workshop - Communicating science - invitation only ECAS01
External
Ended Now live Upcoming
 
Tue 21 Oct 2025
08:15 - 09:15
SAT
Satellite Symposium: : A Shot in the Arm: Leveraging Combination Vaccines for Global Health Impact (a PeerVoice symposium supported by an educational grant from Moderna) SAT05
Auditorium 2 - Breakout
Ended Now live Upcoming
09:30 - 10:30
PLE
Science, Public Health, and Funding in a changing world PLE02
Auditorium 1 - Plenary Hall
Ended Now live Upcoming
10:30 - 11:00
Coffee Break COF03
Exhibition hall
Ended Now live Upcoming
11:00 - 12:30
SCS
Epidemiology and surveillance SCS05
Auditorium 1 - Plenary Hall
Chairs
Monika REDLBERGER-FRITZ
Medical University Vienna, Austria
Read more
Marco DEL RICCIO
University of Florence, Italy
Read more
Ended Now live Upcoming
  1. Age at First Influenza A Virus Infection in Children and Impact of Influenza Vaccination
    To be confirmed
  2. Association of influenza viral genetic information with disease severity markers in hospitalized patients
    To be confirmed
  3. Population-based Surveillance shows Burden of Hospitalisations and Severe Disease due to hMPV, RSV, and Influenza in Older Adults
    To be confirmed
  4. Impact of COVID-19 non-pharmaceutical interventions on antibody waning and the resurgence of human respiratory syncytial virus, seasonal coronavirus and influenza virus in a prospective cohort in The Netherlands
    Channah GAASBEEKRIVM, Netherlands
  5. Epidemiology of hospitalizations in older adults with lab-confirmed hMPV infection: A 14-year time series
    To be confirmed
  6. Epidemiology of human coronaviruses and impact of SARS-CoV-2 vaccination in paediatric patients in Hong Kong
    To be confirmed
SCS
Virus Structure and replication SCS06
Auditorium 2 - Breakout
Chairs
Ed HUTCHINSON
ESWI Board Member, University of Glasgow
Read more
Lisa BAUER
Erasmus MC, Netherlands
Read more
Ended Now live Upcoming
  1. Proteomic analysis of the subcellular reorganization during Influenza A infection in human cells
    To be confirmed
  2. Influenza NS1-Mediated N(6)-Methyladenosine Modification Controls NS mRNA Splicing
    Yingyin LIAOThe University of Hong Kong, Hong Kong SAR China
  3. Reassortment dynamics between clade 2.3.2.1 and 2.3.4.4b A(H5) influenza viruses
    To be confirmed
SPI
Lessons learned: how scientific evidence helps policy SPI03
Auditorium 3 - Breakout
Ended Now live Upcoming
  1. NITAGs and Evidence for Influenza Vaccine Recommendations in Middle Income Countries
    To be confirmed
12:30 - 14:00
Lunch LUN02
Exhibition hall
Ended Now live Upcoming
12:45 - 13:45
SAT
Satellite Symposium organised by Sanofi SAT06
Auditorium 2 - Breakout
Ended Now live Upcoming
14:00 - 15:30
SCS
Pharmaceutical and non pharmaceutical intervention SCS07
Auditorium 1 - Plenary Hall
Chairs
Peter OPENSHAW
ESWI Board Member, Imperial College
Read more
Nisreen OKBA
Icahn School of Medicine at Mount Sinai, United States
Ended Now live Upcoming
  1. Estimated Relative Effectiveness and Public Health Impact of Cell-Based Versus Egg Based Influenza Vaccines During the 2023–2024 Season in the United States
    Alicia STEINCSL Seqirus, Australia
  2. Effectiveness of 2024/25 COVID-19 vaccines against symptomatic SARS-CoV-2 infection in the target group for vaccination, European VEBIS primary care multicentre study, autumn/winter 2024/25
    To be confirmed
  3. Differential protection of prior infection and repeated vaccination against SARS-CoV-2 infection in Omicron BA.2 to JN.1 predominance: a prospective cohort study
    Nicole Ngai Yung TSANGThe University of Hong Kong, Hong Kong SAR China
  4. Vaccine effectiveness against medically attended influenza at primary care level in the paediatric population, 2024/25 season, Europe
    To be confirmed
  5. IMMUNOGENICITY AND SAFETY OF HIGH DOSE FORMULATIONS OF MF59-ADJUVANTED CELL-DERIVED INFLUENZA VACCINE IN ADULTS AGED 50 YEARS AND OLDER: TWO PHASE 2 RANDOMISED CONTROLLED TRIALS
    To be confirmed
SCS
Mathematical modelling and projections, including limitations SCS08
Auditorium 2 - Breakout
Chair
Colin RUSSELL
ESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands
Read more
Ended Now live Upcoming
  1. A Framework for Measuring Population Immunity Against Influenza Using Individual Antibody Titers
    To be confirmed
  2. serojump: A Bayesian tool for inferring infection timing and antibody kinetics from longitudinal serological data
    David HODGSONLondon School of Hygiene and Tropical Medicine, UK
  3. Integrating Serology and PCR to Infer RSV Infection Dynamics and Correlates of Protection in a Community Cohort in The Gambia
    Thushan DE SILVAUniversity of Sheffield, UK
  4. Joint reconstruction of influenza A(H1N1) and A(H3N2) antibody dynamics to estimate the risk of influenza virus infection
    To be confirmed
  5. Investigating the predictive power of machine learning algorithms for antigenic novelty of influenza H3 viruses
    To be confirmed
  6. Comparative Pre-symptomatic Transmission Potential of Influenza A and SARS-CoV-2 in Households
    Chengyao ZHANGUniversity of Hong Kong, Hong Kong SAR China
SPI
Implementation of National Immunisation Programmes SPI04
Auditorium 3 - Breakout
Chairs
Ted VAN ESSEN
ESWI Board Member, Netherlands
Read more
George KASSIANOS
ESWI Board Member, G Kassianos
Read more
Ended Now live Upcoming
  1. Preliminary observation of impact of Maternal RSV Vaccination on Infant Hospitalizations in Mendoza, Argentina: A Comparative Study of the 2023 and 2024 Seasons
    To be confirmed
  2. Effectiveness of Maternal Influenza Vaccination in Preventing Influenza Infection in Infants Aged ≤ 6 Months in Korea
    To be confirmed
15:30 - 16:00
Coffee Break COF04
Exhibition hall
Ended Now live Upcoming
16:00 - 17:00
SAT
Satellite Symposium organised by CSL Seqirus SAT07
Auditorium 2 - Breakout
Ended Now live Upcoming
17:00 - 18:30
POS
Poster presentations and refreshments POS01
Poster Halls
Ended Now live Upcoming
18:30 - 19:30
ECAS
Early Career Scientists panel discussion - Life after Phd - invitation only ECAS02
External
Ended Now live Upcoming
 
Wed 22 Oct 2025
08:15 - 09:15
SAT
Satellite Symposium organised by the Global Influenza Initiative: Preventing influenza to safeguard aging populations SAT08
Auditorium 2 - Breakout
Ended Now live Upcoming
09:30 - 10:30
PLE
Keynotes PLE03
Auditorium 1 - Plenary Hall
Ended Now live Upcoming
10:30 - 11:00
Coffee Break COF05
Exhibition hall
Ended Now live Upcoming
11:00 - 12:30
SCS
Future vaccination strategies - PART 2 SCS09
Auditorium 1 - Plenary Hall
Chairs
Florian KRAMMER
ESWI Board Member, Medical University of Vienna, Austria
Read more
Marios KOUTSAKOS
University of Melbourne, Australia
Read more
Ended Now live Upcoming
  1. A Novel Antigenically Central HA mRNA Vaccine Confers Humoral and Cellular Immune Responses and Protects Ferrets Against Challenge With a Heterologous A(H5) Clade 2.3.4.4b Highly Pathogenic Avian Influenza Virus
    To be confirmed
  2. Breast milk-derived secretory IgA provides broad protection against influenza A virus
    To be confirmed
  3. Hemagglutination inhibition antibody titer as correlate of protection against influenza virus infection: a systematic review and meta-analysis
    Nancy H. L. LEUNGThe University of Hong Kong, Hong Kong SAR China
  4. Pooled Long-Term Safety Analysis of a Phase 1/2/3 Randomized, Observer-Blind, Controlled Study of the Self-Amplifying mRNA COVID-19 Vaccine ARCT-154 in Adults
    To be confirmed
  5. Decades of Evidence Revisited: A Systematic Review on Anti-Neuraminidase Antibody Responses and Influenza-related Outcomes
    To be confirmed
  6. Immunogenicity and Reactogenicity of an mRNA-Based Seasonal Influenza and SARS-CoV-2 Multicomponent Vaccine (mRNA-1083) in Adults ≥65 Years With Comorbidities
    To be confirmed
SCS
Human challenge studies SCS11
Auditorium 2 - Breakout
Chair
Ab OSTERHAUS
ESWI Board Member, TiHO, Germany
Read more
Ended Now live Upcoming
  1. Disease characteristics and immunological profiles obtained from a newly developed hMPV human challenge model
    Brandon LONDThVIVO, UK
  2. Evolution of Human Metapneumovirus (HMPV) over the last 20 years and superior isolation of HMPV from clinical samples in organoid-derived bronchial cell cultures to isolation in monolayer cell line cultures
    To be confirmed
  3. Challenges and Opportunities in the Development of RSV Challenge Strains for CHIM studies
    To be confirmed
  4. A Study of the Efficacy, Safety and Immunogenicity of mRNA vaccines in an Influenza B Challenge Model in Healthy Adults
    To be confirmed
  5. Development of a Severe Acute Respiratory Syndrome – Coronavirus 2 (SARS-CoV-2) Omicron BA5 human challenge model (HCM) for the assessment of new vaccine and anti-viral therapies in seropositive subjects
    Brandon LONDThVIVO, UK
SCS
Clinical Manifestations, burden of disease and management SCS10
Auditorium 3 - Breakout
Chairs
Marco GOEIJENBIER
ESWI Board Member, Spaarne Gasthuis, Netherlands
Read more
Valentino D'ONOFRIO
Ghent University, Belgium
Read more
Ended Now live Upcoming
  1. Burden of Influenza Hospitalisation (Including With Recent COVID-19) Among Individuals With Immunocompromising Conditions and Other Comorbidities: An Exploratory Analysis Using the INFORM Study Cohort
    To be confirmed
  2. Is clinical outcome pathogen related? Characteristics and Outcomes of ICU Patients with Severe Acute Respiratory Infections: Focusing on Respiratory Syncytial Virus, Human Metapneumovirus, Influenza virus, and Parainfluenza virus
    To be confirmed
  3. Hospital Burden of Respiratory Syncytial Virus (RSV) in Adults Aged 18 to 60 Years in France: A Nationwide Analysis (2018–2023)
    To be confirmed
  4. Clinical outcomes among older adults hospitalized with respiratory syncytial virus and influenza infection – a retrospective study from Israel
    To be confirmed
  5. The Effect of Revaccination and Reinfection on Symptom Severity and Prevalence in a Post Covid-19 Condition Cohort
    To be confirmed
  6. RSV in Patients with Hematological Malignancies: A Multi-centre Retrospective Cohort Study
    To be confirmed
12:30 - 14:00
Lunch LUN03
Exhibition hall
Ended Now live Upcoming
12:45 - 13:45
SAT
Satellite Symposium SAT09
Auditorium 2 - Breakout
Ended Now live Upcoming
14:00 - 15:30
SCS
Antiviral and immune therapy SCS12
Auditorium 1 - Plenary Hall
Chairs
Adolfo GARCÍA-SASTRE
Icahn School of Medicine at Mount Sinai, United States
Read more
Josefine SCHROEDER
Jena University Hospital, Germany
Read more
Ended Now live Upcoming
  1. Effectiveness of the approved antiviral drugs for mild/moderate infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Hong Kong
    To be confirmed
  2. Impact of Antiviral Timing and Vaccination on Viral Shedding in Hospitalized Older Adults with COVID-19 During Omicron Predominance
    To be confirmed
  3. Analysis of potential drug combinations against influenza by specifically targeting the viral polymerase
    To be confirmed
  4. Treatment with pictilisib-loaded lipid nanoparticles reduces influenza A virus infection in vitro and ex vivo
    Josefine SCHROEDERJena University Hospital, Germany
  5. Comparative assessment of in vivo antiviral activity of anti-influenza drugs (AD ASTRA)
    To be confirmed
SCS
Virus evolution and strain selection SCS13
Auditorium 2 - Breakout
Chairs
Ron FOUCHIER
Erasmus MC, Netherlands
Read more
Kairat TABYNOV
Kazakh National Agrarian Research University, Kazakhstan
Read more
Ended Now live Upcoming
  1. High-throughput neutralization measurements correlate strongly with evolutionary success of human influenza strains
    To be confirmed
  2. Antigenic mapping of influenza A viruses using deep learning-based prediction of hemagglutination inhibition titers
    To be confirmed
  3. Site specific predictability of amino acid substitutions of seasonal influenza viruses
    Annelies DE ROOIJAmsterdam University Medical Center, Netherlands
  4. Informal settlements and COVID-19: viral phylodynamic, respiratory microbiome, and public health implications.
    To be confirmed
  5. Linking Poultry Supply Chains and Marketing Practices to the Detection of Novel Genotypes Viruses in Bangladeshi Live Bird Markets
    To be confirmed
SPI
Empowering Preparedness: Harnessing Science to Manage Epidemics and Pandemics SPI05
Auditorium 3 - Breakout
Chair
Gülsah GABRIEL
ESWI Board Member, Leibniz Institute of Virology, Germany
Read more
Ended Now live Upcoming
  1. Leibniz Lab Pandemic Preparedness: inter- and transdisciplinary approaches towards pandemic resilience in science and society
    To be confirmed
15:30 - 16:00
Coffee Break COF06
Exhibition hall
Ended Now live Upcoming
16:00 - 17:30
SCS
Threats from the animal world SCS14 PLE
Auditorium 1 - Plenary Hall
Chairs
Stacey SCHULTZ-CHERRY
St Jude Children's Research Hospital, United States
Read more
Kevin CIMINSKI
University Medical Center Freiburg, Germany
Read more
Ended Now live Upcoming
  1. Genomic insights into the broadening host range of clade 2.3.4.4b H5 avian influenza viruses
    To be confirmed
  2. Emergence of a Novel Reassortant Clade 2.3.2.1e Avian Influenza A/H5N1 Virus Associated with Human Cases in Cambodia
    To be confirmed
  3. Increased attachment to and replication of recent avian H5N1 influenza A viruses from clade 2.3.4.4b in human airway epithelial cells
    Lisa BAUERErasmus MC, Netherlands
  4. Bovine Myxovirus Resistance Protein 1 mediates antiviral activity against human and avian influenza A viruses
    To be confirmed
17:30 - 19:00
POS
Poster presentations and refreshments POS02
Poster Halls
Ended Now live Upcoming
 
Thu 23 Oct 2025
08:15 - 09:15
SAT
Satellite Symposium organised by Pfizer SAT10
Auditorium 1 - Plenary Hall
Ended Now live Upcoming
SAT
Satellite Symposium organised by the ESWI Influenza Diabetes Community and supported by IFPMA SAT11
Auditorium 2 - Breakout
Chair
Tor BIERING-SØRENSEN
University of Copenhagen, Denmark
Read more
Ended Now live Upcoming
  1. The Impact of Glycemic Variability on Influenza Outcomes in Intensive Care Patients
    To be confirmed
09:30 - 10:30
ECAS
Early Career Scientist Awards and Presentations ECAS03
Auditorium 1 - Plenary Hall
Chairs
Carolien VAN DE SANDT
ESWI Associate Member, The University of Melbourne at the Doherty Institute, Australia
Read more
Colin RUSSELL
ESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands
Read more
Ended Now live Upcoming
10:30 - 11:00
Coffee Break COF07
Exhibition hall
Ended Now live Upcoming
11:00 - 12:30
SCS
Late Breakers: novel and outstanding discoveries SCS15
Auditorium 1 - Plenary Hall
Chairs
Sylvie VAN DER WERF
ESWI Associate Member, Institut Pasteur, France
Read more
Kirsty SHORT
ESWI Associate Member, University of Queensland, Australia
Read more
Ended Now live Upcoming
12:30 - 14:00
Lunch LUN04
Exhibition hall
Ended Now live Upcoming
14:00 - 15:00
SAT
Satellite Symposium organised by the ISOLDA consortium: Improved vaccination Strategies for OLDer Adults (ISOLDA) – a Horizon 2020 project SAT12
Auditorium 1 - Plenary Hall
Chair
Ab OSTERHAUS
ESWI Board Member, TiHO, Germany
Read more
Ended Now live Upcoming
SAT
Satellite Symposium SAT13
Auditorium 2 - Breakout
Ended Now live Upcoming
15:10 - 16:00
PLE
Closing and keynote PLE04
Auditorium 1 - Plenary Hall
Chairs
Colin RUSSELL
ESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands
Read more
Ab OSTERHAUS
ESWI Board Member, TiHO, Germany
Read more
Stefania MAGGI
ESWI Board Member, National Research Council of Italy, Italy
Read more
Marco GOEIJENBIER
ESWI Board Member, Spaarne Gasthuis, Netherlands
Read more
Ended Now live Upcoming
 

Programme chairs

Ab OSTERHAUS
ESWI Board Member, TiHO, Germany
Adolfo GARCÍA-SASTRE
Icahn School of Medicine at Mount Sinai, United States
Anders MADSEN
Haukeland University Hospital, Norway
Carolien VAN DE SANDT
ESWI Associate Member, The University of Melbourne at the Doherty Institute, Australia
Colin RUSSELL
ESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands
Debby VAN RIEL
ESWI Associate Member, Erasmus MC, Netherlands
Ed HUTCHINSON
ESWI Board Member, University of Glasgow
Florian KRAMMER
ESWI Board Member, Medical University of Vienna, Austria
George KASSIANOS
ESWI Board Member, G Kassianos
Guus RIMMELZWAAN
University of Veterinary Medicine, Hannover, Germany
Gülsah GABRIEL
ESWI Board Member, Leibniz Institute of Virology, Germany
Josefine SCHROEDER
Jena University Hospital, Germany
Kairat TABYNOV
Kazakh National Agrarian Research University, Kazakhstan
Kevin CIMINSKI
University Medical Center Freiburg, Germany
Kevin SELVA
Doherty Institute, University of Melbourne, Australia
Kirsty SHORT
ESWI Associate Member, University of Queensland, Australia
Lisa BAUER
Erasmus MC, Netherlands
Marco DEL RICCIO
University of Florence, Italy
Marco GOEIJENBIER
ESWI Board Member, Spaarne Gasthuis, Netherlands
Marios KOUTSAKOS
University of Melbourne, Australia
Monika REDLBERGER-FRITZ
Medical University Vienna, Austria
Nisreen OKBA
Nisreen OKBA
Icahn School of Medicine at Mount Sinai, United States
Paula TÄHTINEN
ESWI Board Member, Turku University Hospital and University of Turku, Finland
Peter OPENSHAW
ESWI Board Member, Imperial College
Ron FOUCHIER
Erasmus MC, Netherlands
Stacey SCHULTZ-CHERRY
St Jude Children's Research Hospital, United States
Stefania MAGGI
ESWI Board Member, National Research Council of Italy, Italy
Sylvie VAN DER WERF
ESWI Associate Member, Institut Pasteur, France
Ted VAN ESSEN
ESWI Board Member, Netherlands
Tor BIERING-SØRENSEN
University of Copenhagen, Denmark
Valentino D'ONOFRIO
Ghent University, Belgium